| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/JNNP-2012-304670 |
| P698 | PubMed publication ID | 23538070 |
| P50 | author | Leonard H van den Berg | Q56999697 |
| Pieter A van Doorn | Q66672518 | ||
| Bart C Jacobs | Q66672643 | ||
| Teun van Gelder | Q87686764 | ||
| Ivo N van Schaik | Q91890462 | ||
| Esther Brusse | Q91997266 | ||
| Nicolette C Notermans | Q95290548 | ||
| Krista Kuitwaard | Q98901052 | ||
| Anneke J van der Kooi | Q114292158 | ||
| P2093 | author name string | Marinus Vermeulen | |
| Anne P Tio-Gillen | |||
| W-Ludo van der Pol | |||
| Wouter van Rijs | |||
| P433 | issue | 8 | |
| P921 | main subject | demyelinating polyneuropathy | Q18556682 |
| P304 | page(s) | 859-861 | |
| P577 | publication date | 2013-03-28 | |
| P1433 | published in | Journal of Neurology, Neurosurgery and Psychiatry | Q1599804 |
| P1476 | title | Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy | |
| P478 | volume | 84 |
| Q90575546 | Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy |
| Q38336186 | Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels |
| Q86421395 | Dosing and individualized treatment - patient-centric treatment: changing practice guidelines |
| Q86421453 | Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation |
| Q39424607 | Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? |
| Q39067335 | Immunoglobulins: current understanding and future directions |
| Q39107736 | Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection |
| Q37339743 | Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q88155316 | Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies |
| Q92277154 | Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis |
| Q33419638 | Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe |
| Q64239878 | Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy |
| Q38270717 | Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach |
| Q86421558 | Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies |
| Q50748736 | Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q44954147 | Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study |
| Q26745685 | Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies |
Search more.